Cinacalcet
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-CINACALCET |
|---|---|
| Type | Drug |
| Aliases | MimparaSensiparЦинакалцет |
| Status | reviewed 2026-07-11 | pending_clinical_signoff |
| Diseases | DIS-PARATHYROID-CARCINOMA |
| Sources | SRC-NCCN-THYROID-2025 |
Drug Facts
| Class | Calcimimetic (calcium-sensing receptor allosteric agonist) |
|---|---|
| Mechanism | Allosterically increases the sensitivity of the parathyroid calcium-sensing receptor (CaSR) to extracellular calcium, suppressing PTH secretion and lowering serum calcium. Acts on the biochemical consequence of the disease (PTH-driven hypercalcemia) rather than the tumor itself — no direct antitumor / cytotoxic effect. |
| Typical dosing | Initiate 30 mg PO BID. Titrate no more frequently than every 2-4 weeks through sequential doses of 30 mg BID → 60 mg BID → 90 mg BID → 90 mg TID → 90 mg QID (maximum labeled dose) to normalize serum calcium. Take with food (improves bioavailability). Check serum calcium within 1 week of initiation or any dose change. FDA-approved specifically for hypercalcemia of parathyroid carcinoma (also approved for secondary hyperparathyroidism in dialysis-dependent CKD and severe hypercalcemia in primary hyperparathyroidism when parathyroidectomy is not appropriate). |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-07-11 |
Notes
STUB pending clinical co-lead signoff (CHARTER §6.1 — dev-mode- exempted draft content, not published/verified clinical advice). Cinacalcet is the only FDA-approved medical therapy specifically labeled for hypercalcemia of parathyroid carcinoma. It has no cytostatic/cytotoxic effect on the tumor — it controls the biochemical consequence (PTH-driven hypercalcemia) in unresectable, recurrent, or metastatic disease. Distinct from bisphosphonates (DRUG-ZOLEDRONATE) / denosumab (DRUG-DENOSUMAB) — already in the KB — which act on osteoclast-mediated bone turnover to prevent skeletal-related events from bone metastases rather than suppressing PTH secretion; the two mechanisms are complementary and may be used concurrently in refractory hypercalcemia, per the parent Disease entity's narrative (DIS-PARATHYROID-CARCINOMA).
Used By
Diseases
DIS-PARATHYROID-CARCINOMA- Parathyroid carcinoma
Regimens
REG-CINACALCET-HYPERCALCEMIA- Cinacalcet for hypercalcemia of parathyroid carcinoma